Application of a PBPK Model of Rivaroxaban to Prospective Simulations of Drug-Drug-Disease Interactions with Protein Kinase Inhibitors in CA-VTE.

Eleanor Jing Yi CheongDaniel Zhi Wei NgSheng Yuan ChinZiteng Wang Eric Chun Yong Chan

Published in: British journal of clinical pharmacology (2021)

We established a PBPK-DDDI model to prospectively evaluate clinically relevant interactions between rivaroxaban and PKIs for the safe and efficacious management of CA-VTE.

Keyphrases

venous thromboembolism
atrial fibrillation
pulmonary embolism
adverse drug
protein kinase
emergency department
amino acid